Novavax (NVAX) Misses Q2 EPS by $12.03, Cuts FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights
August 8, 2022 4:02 PM EDTReceived FDA EUA and CDC recommendation for NVX-CoV2373, marking the first protein-based COVID-19 vaccine authorized in the U.S. for adults; with immunizations underwayNuvaxovid and Covovax authorized for adults in 43 countries, with booster authorizations in Japan, Australia and New Zealand as well as, adolescent authorizations in the EU, Australia, India, Japan, and ThailandOver 73 million doses delivered globally to date Progressing variant program with top-line clinical data for Omicron expected near the end of the third quarter of 2022Adjusted revenue guidance to $2 billion to $2.3... More
